Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Meyers

Cardiovascular Disease Chesterfield, MO Medical Doctor

NPI 1225045719 CMS profile 483571

222 S Woods Mill Rd, Ste 310N, Chesterfield, MO 63017

Open in the dashboard

General payments

$3,131

169 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Meyers of Chesterfield, MO is reported in the CMS Open Payments database as having received $3,131 across 169 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $31 1
2024 General $293 2
2023 General $139 1
2022 General $32 2
2021 General $1,134 69
2020 General $546 33
2019 General $956 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Meyers
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to David Meyers were reported at $31. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year David Meyers Cardiovascular Disease median Middle half National median
2019 $956 $450 $127–$1,392 $163
2020 $546 $242 $77–$751 $114
2021 $1,134 $335 $101–$1,037 $132
2022 $32 $395 $121–$1,211 $149
2023 $139 $443 $136–$1,283 $160
2024 $293 $450 $136–$1,323 $164
2025 $31 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $398 25 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $361 18 payments
  3. Boston Scientific Corporation $323 5 payments
  4. Amgen Inc. $237 8 payments
  5. AstraZeneca Pharmaceuticals LP $230 16 payments
  6. Actelion Pharmaceuticals US, Inc. $185 14 payments
  7. Novartis Pharmaceuticals Corporation $182 16 payments
  8. Abbott Laboratories $172 1 payment
  9. Amarin Pharma Inc. $145 12 payments
  10. United Therapeutics Corporation $129 7 payments
  11. Other $769 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,131 169 payments
Products named General payments · program years 2019–2025
  1. XARELTO $398 25 payments
  2. Repatha $237 8 payments
  3. UPTRAVI $185 14 payments
  4. ENTRESTO $182 16 payments
  5. Xience Skypoint $172 1 payment
  6. OFEV $165 6 payments
  7. SPIRIVA RESPIMAT $146 10 payments
  8. Vascepa $145 12 payments
  9. WATCHMAN Access System $139 1 payment
  10. ORENITRAM $107 6 payments
  11. Other $1,591 101 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

169 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record